Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 52M | 150.7% |
| Gross Profit | 12M | 149.4% |
| Cost of Revenue | 40M | 9.5% |
| Operating expense | 68M | 5% |
| Net Income | -30M | 52.3% |
| EBITDA | -16M | 719% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 314M | 10.8% |
| Total Liabilities | 684M | 1.8% |
| Shares Outstanding | 195M | 3.3% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -35M | 390.3% |
| Cash from investing | -170,000 | 116.9% |
| Cash from financing | -9.1M | 69.7% |
EPS
Financial Highlights for Esperion Therapeutics in Q3 '24
Esperion Therapeutics reported a revenue of 52M, which is a 150.7% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 12M, marking a 149.4% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 40M, a -9.5% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 68M, showing a -5% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -30M, showing a 52.3% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -16M, showing a -719% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Esperion Therapeutics with growth in revenue, gross profit, and net income. A decline in EBITDA signals potential operational challenges or increased costs.
